Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

Mobocertinib (TAK‐788) is a tyrosine kinase inhibitor under investigation for treatment of non–small cell lung cancer with activating EGFR exon 20 insertions. This study examined the safety; tolerability; pharmacokinetics (PK), including food effects; and bioavailability of mobocertinib in healthy v...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Steven, Jin, Shu, Griffin, Celina, Feng, Zhongling, Lin, Jianchang, Baratta, Mike, Brake, Rachael, Venkatakrishnan, Karthik, Gupta, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453943/
https://www.ncbi.nlm.nih.gov/pubmed/34118178
http://dx.doi.org/10.1002/cpdd.951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453943/
https://www.ncbi.nlm.nih.gov/pubmed/34118178
http://dx.doi.org/10.1002/cpdd.951

Ejemplares similares